Getting PUMPed Up On ProPetro (Rating Upgrade)
ProPetro Holding Corp.'s Q4 2024 results show undervaluation, resilient Permian growth, and PROPWR's future potential. Click ...
Celcuity's High-Stakes Oncology Bet Is Underappreciated
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...